B Cell

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.

Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.

CHICAGO — Negative circulating tumor DNA status contributed to a PFS benefit for patients with previously untreated diffuse large B-cell lymphoma, according to research presented at ASCO Annual Meeting.

A small percentage of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a second infusion of tisagenlecleucel had clinically meaningful responses, data from a retrospective study showed.

Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Treatment with inebilizumab was associated with reduction in aquaporin-4 antibody titers and B cells for those with neuromyelitis optica spectrum disorder, according to an expert at ECTRIMS 2022.

In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.

Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.